BR112021020601A2 - Compostos contra câncer contendo mutações do egfr resistentes ao inibidor da tirosina quinase - Google Patents
Compostos contra câncer contendo mutações do egfr resistentes ao inibidor da tirosina quinaseInfo
- Publication number
- BR112021020601A2 BR112021020601A2 BR112021020601A BR112021020601A BR112021020601A2 BR 112021020601 A2 BR112021020601 A2 BR 112021020601A2 BR 112021020601 A BR112021020601 A BR 112021020601A BR 112021020601 A BR112021020601 A BR 112021020601A BR 112021020601 A2 BR112021020601 A2 BR 112021020601A2
- Authority
- BR
- Brazil
- Prior art keywords
- tyrosine kinase
- kinase inhibitor
- egfr mutations
- compounds containing
- cancer compounds
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 201000011510 cancer Diseases 0.000 title abstract 3
- 230000035772 mutation Effects 0.000 title abstract 3
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 title abstract 3
- 239000005483 tyrosine kinase inhibitor Substances 0.000 title abstract 3
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 title abstract 3
- 108060006698 EGF receptor Proteins 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 title abstract 2
- LPFWVDIFUFFKJU-UHFFFAOYSA-N 1-[4-[4-(3,4-dichloro-2-fluoroanilino)-7-methoxyquinazolin-6-yl]oxypiperidin-1-yl]prop-2-en-1-one Chemical compound C=12C=C(OC3CCN(CC3)C(=O)C=C)C(OC)=CC2=NC=NC=1NC1=CC=C(Cl)C(Cl)=C1F LPFWVDIFUFFKJU-UHFFFAOYSA-N 0.000 abstract 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 abstract 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 abstract 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 abstract 1
- DUYJMQONPNNFPI-UHFFFAOYSA-N osimertinib Chemical compound COC1=CC(N(C)CCN(C)C)=C(NC(=O)C=C)C=C1NC1=NC=CC(C=2C3=CC=CC=C3N(C)C=2)=N1 DUYJMQONPNNFPI-UHFFFAOYSA-N 0.000 abstract 1
- 229960003278 osimertinib Drugs 0.000 abstract 1
- 229950009876 poziotinib Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0031—Rectum, anus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Hospice & Palliative Care (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962835343P | 2019-04-17 | 2019-04-17 | |
| PCT/US2020/028540 WO2020214824A1 (en) | 2019-04-17 | 2020-04-16 | Compounds against cancer bearing tyrosine kinase inhibitor resistant egfr mutations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112021020601A2 true BR112021020601A2 (pt) | 2021-12-07 |
Family
ID=72837936
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112021020601A BR112021020601A2 (pt) | 2019-04-17 | 2020-04-16 | Compostos contra câncer contendo mutações do egfr resistentes ao inibidor da tirosina quinase |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20220175779A1 (enExample) |
| EP (1) | EP3956035A4 (enExample) |
| JP (1) | JP7709384B2 (enExample) |
| KR (1) | KR20220004089A (enExample) |
| CN (1) | CN113993592A (enExample) |
| AU (1) | AU2020257395A1 (enExample) |
| BR (1) | BR112021020601A2 (enExample) |
| CA (1) | CA3132819A1 (enExample) |
| IL (1) | IL287115A (enExample) |
| MX (1) | MX2021012705A (enExample) |
| PH (1) | PH12021552579A1 (enExample) |
| SG (1) | SG11202111120VA (enExample) |
| WO (1) | WO2020214824A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2021010265A (es) | 2019-02-26 | 2021-09-23 | Janssen Biotech Inc | Terapias de combinacion y estratificacion de pacientes con anticuerpos anti-egfr/c-met biespecificos. |
| US12629375B2 (en) | 2019-03-29 | 2026-05-19 | Board Of Regents, The University Of Texas System | Compounds with anti-tumor activity against cancer cells bearing HER2 exon 21 insertions |
| MY208668A (en) | 2019-05-14 | 2025-05-23 | Janssen Biotech Inc | Combination therapies with bispecific anti-egfr/c-met antibodies and 3rd generation egfr tyrosine kinase inhibitors |
| US11850248B2 (en) | 2019-05-14 | 2023-12-26 | Yuhan Corporation | Therapies with 3rd generation EGFR tyrosine kinase inhibitors |
| BR112022015140A2 (pt) | 2020-02-12 | 2022-10-11 | Janssen Biotech Inc | Tratamento de pacientes que têm mutações de salto do éxon 14 de c-met |
| EP4284950A4 (en) * | 2021-01-29 | 2024-12-25 | Board of Regents, The University of Texas System | METHODS OF TREATMENT OF CANCER USING KINASE INHIBITORS |
| US20240108623A1 (en) * | 2021-01-29 | 2024-04-04 | Board Of Regents, The University Of Texas System | Methods of treating cancer with poziotinib |
| WO2023129667A1 (en) | 2021-12-30 | 2023-07-06 | Biomea Fusion, Inc. | Pyrazine compounds as inhibitors of flt3 |
| CN115998743B (zh) * | 2023-01-16 | 2024-05-28 | 威尚（上海）生物医药有限公司 | 喹唑啉类化合物在克服奥希替尼耐药中的用途 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3120851A1 (en) * | 2015-07-21 | 2017-01-25 | Pangaea Biotech S.L. | 4-amino-6-(2,6-dichlorophenyl)-8-methyl-2-(phenylamino)-pyrido[2,3-d]pyrimidin-7(8h)-one for treatment of solid cancers |
| EP3458064A1 (en) * | 2016-05-18 | 2019-03-27 | Boehringer Ingelheim International GmbH | Anticancer combination therapy |
| BR112019010020A2 (pt) * | 2016-11-17 | 2019-08-20 | Univ Texas | compostos com atividade anti-tumoral contra células cancerosas contendo mutações de egfr ou her2 exon 20 |
| WO2018213770A1 (en) * | 2017-05-19 | 2018-11-22 | Regents Of The University Of Minnesota | Therapeutic methods |
| JP7386174B2 (ja) * | 2018-03-27 | 2023-11-24 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | Ｈｅｒ２エクソン１９変異を有するがん細胞に対する抗腫瘍活性を有する化合物 |
| SG11202012064PA (en) * | 2018-06-25 | 2021-01-28 | Spectrum Pharmaceuticals Inc | Combination of poziotinib with cytotoxic agent and/or other molecularly targeted agent and use thereof |
| KR20210066819A (ko) * | 2018-09-04 | 2021-06-07 | 레인 세러퓨틱스 인코포레이티드 | Her-유도 암을 치료 또는 예방하기 위한 화합물, 조성물 및 방법 |
| MX2021010265A (es) * | 2019-02-26 | 2021-09-23 | Janssen Biotech Inc | Terapias de combinacion y estratificacion de pacientes con anticuerpos anti-egfr/c-met biespecificos. |
| US20220143023A1 (en) * | 2019-03-29 | 2022-05-12 | Board Of Regents, The University Of Texas System | Compounds with anti-tumor activity against cancer cells bearing egfr or her2 exon 20 insertions |
| US12629375B2 (en) * | 2019-03-29 | 2026-05-19 | Board Of Regents, The University Of Texas System | Compounds with anti-tumor activity against cancer cells bearing HER2 exon 21 insertions |
-
2020
- 2020-04-16 JP JP2021561673A patent/JP7709384B2/ja active Active
- 2020-04-16 AU AU2020257395A patent/AU2020257395A1/en not_active Abandoned
- 2020-04-16 KR KR1020217037150A patent/KR20220004089A/ko not_active Ceased
- 2020-04-16 PH PH1/2021/552579A patent/PH12021552579A1/en unknown
- 2020-04-16 EP EP20792247.7A patent/EP3956035A4/en active Pending
- 2020-04-16 BR BR112021020601A patent/BR112021020601A2/pt not_active Application Discontinuation
- 2020-04-16 WO PCT/US2020/028540 patent/WO2020214824A1/en not_active Ceased
- 2020-04-16 SG SG11202111120VA patent/SG11202111120VA/en unknown
- 2020-04-16 MX MX2021012705A patent/MX2021012705A/es unknown
- 2020-04-16 CA CA3132819A patent/CA3132819A1/en active Pending
- 2020-04-16 CN CN202080044361.XA patent/CN113993592A/zh active Pending
- 2020-04-16 US US17/604,560 patent/US20220175779A1/en active Pending
-
2021
- 2021-10-10 IL IL287115A patent/IL287115A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2021012705A (es) | 2021-11-12 |
| CN113993592A (zh) | 2022-01-28 |
| JP2022529945A (ja) | 2022-06-27 |
| AU2020257395A1 (en) | 2021-11-04 |
| WO2020214824A1 (en) | 2020-10-22 |
| PH12021552579A1 (en) | 2022-08-01 |
| CA3132819A1 (en) | 2020-10-22 |
| IL287115A (en) | 2021-12-01 |
| SG11202111120VA (en) | 2021-11-29 |
| EP3956035A1 (en) | 2022-02-23 |
| KR20220004089A (ko) | 2022-01-11 |
| JP7709384B2 (ja) | 2025-07-16 |
| EP3956035A4 (en) | 2023-01-25 |
| US20220175779A1 (en) | 2022-06-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP19043254A (es) | Compuestos con actividad antitumoral contra células cancerosas que tienen mutaciones en el exón 20 de egfr o her2 | |
| MX2021012705A (es) | Compuestos con actividad antitumoral contra las celulas cancerosas que portan mutaciones en el receptor del factor de crecimiento epidermico (egfr) resistentes al inhibidor de la tirosina quinasa. | |
| BR112021017350A2 (pt) | Combinação de conjugado de anticorpo-derivado de pirrolobenzodiazepina e inibidor de parp | |
| PH12019500214A1 (en) | Substituted thiazolo-pyridine compounds as malt1 inhibitors | |
| EP4497474A3 (en) | Methods of treating rheumatic diseases using trimetazidine-based compounds | |
| JOP20190151B1 (ar) | مركبات أمينو - ترايازولو بيريدين واستخدامها في علاج سرطان | |
| BR112022007595A2 (pt) | Métodos para tratar doença de alzheimer | |
| MX2020011234A (es) | Moduladores de receptor similar al dominio de oligomerizacion de union a nucleotidos que contiene dominio de pirina 3 (nlrp3). | |
| BR112013000651A2 (pt) | combinações de inibidores de cinase para o tratamento de câncer. | |
| BR112014019052A8 (pt) | Inibidores seletivos de cdk8/cdk19 e seu uso em métodos antimetastáticos e quimiopreventivos para câncer | |
| BR112015026297A2 (pt) | terapia combinada composta por um inibidor tor quinase e um composto de 5-quinazolinona substituído para o tratamento de câncer | |
| MX2020009773A (es) | Terapia de combinacion. | |
| BR112019011199A2 (pt) | método para tratar um indivíduo que tem um câncer de próstata e kits | |
| BR112016027043A8 (pt) | combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer | |
| PH12020500096A1 (en) | Therapeutic combination of a third generation egfr tyrosine kinase inhibitor and a raf inhibitor | |
| MX2020001253A (es) | Combinacion terapeutica de un inhibidor tirosina quinasa del egfr de tercera generacion y un inhibidor de quinasa dependiente de ciclina. | |
| BR112022010278A2 (pt) | Terapia combinada que envolve compostos macrocíclicos de diarila | |
| PH12017501130A1 (en) | Indenyl compounds, pharmaceutical compositions, and medical uses thereof | |
| AU2016380190A8 (en) | Deuterated compounds for treating cancer and related diseases and conditions, and compositions and methods thereof | |
| MX2020001727A (es) | Terapia de combinacion. | |
| BR112022010702A2 (pt) | Macrociclos para uso no tratamento de doenças | |
| PH12021551276A1 (en) | Combination therapy for the treatment of cancer | |
| BR112021019376A2 (pt) | Compostos com atividade antitumor contra células cancerígenas transportando inserções de éxon 21 de her2 | |
| MX2022000082A (es) | Composiciones terapeuticas y metodos para tratar canceres. | |
| BR112019008516A2 (pt) | derivado de 3,4-bipiridil pirazol, e método de preparação para o mesmo e aplicação médica do mesmo |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |